Increased serum Neurofilament light chain levels in Parkinson’s Disease patients carrying the p.A53T SNCA mutation: Data from the PPMI study
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
Serum neurofilament light chain (NfL) levels, a marker of axonal damage, are generally elevated in neurodegenerative conditions, but results in idiopathic Parkinson’s Disease (iPD) have been inconsistent. The p.A53T mutation in the SNCA gene usually leads to a severe, rapidly progressing genetic form of PD.
Objectives
Assessing the possible use of serum NfL as a marker of ongoind neurodegeneration in A53T-PD.
Methods
Using a propensity score matching based technique with data from the Parkinson’s Progression Markers Initiative, A53T-PD participants were matched, in a 3:1 ratio, to iPD patients and healthy controls by age and disease duration, where applicable.
Results
After matching, 18 A53T-PD, 54 iPD, and 54 controls were analyzed. Serum NfL was significantly higher in A53T-PD (9.82 [8.02-18.1] pg/ml) compared to HC (7.54 [5.76-10.1]) or iPD (8.59 [6.86-11.1]) [overall p=0.049].
Conclusion
The increase in serum NfL points to a more aggressive neurodegenerative process in A53T-PD compared to iPD. This finding may help design and implement Disease-modifying treatments (DMTs) in this select group of prototypical genetic PD.
